Boston Scientific Statistics
Boston Scientific (BSX) Stock Statistics & Valuation Metrics
Total Valuation
Boston Scientific has a market cap or net worth of CHF 53.92B. The enterprise value is CHF 74.91B.
- Market Cap
- CHF 53.92B
- Enterprise Value
- CHF 74.91B
Share Statistics
Boston Scientific has 1,449,473,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,449,473,300
- Owned by Insiders
- 0.17%
- Owned by Institutions
- 57.86%
Financial Efficiency
Boston Scientific’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 8.78%.
- Return on Equity (ROE)
- 0.12
- Return on Assets (ROA)
- 0.07
- Return on Invested Capital (ROIC)
- 8.78%
- Return on Capital Employed (ROCE)
- 0.10
- Revenue Per Employee
- 340.24K
- Profits Per Employee
- 48.92K
- Employee Count
- 59,000
- Asset Turnover
- 0.46
- Inventory Turnover
- 2.11
Valuation Ratios
The current PE Ratio of Boston Scientific is 19.04. Boston Scientific’s PEG ratio is 0.75.
- PE Ratio
- 19.04
- PS Ratio
- 3.10
- PB Ratio
- 2.55
- Price to FCF
- 19.64
- Price to Operating Cash Flow
- 15.44
- PEG Ratio
- 0.75
Income Statement
In the last 12 months, Boston Scientific had revenue of 20.07B and earned 2.89B in profits. Earnings per share was 1.96.
- Revenue
- 20.07B
- Gross Profit
- 13.85B
- Operating Income
- 3.97B
- Pretax Income
- 3.38B
- Net Income
- 2.89B
- EBITDA
- 5.10B
- Earnings Per Share (EPS)
- 1.96
Cash Flow
In the last 12 months, operating cash flow was 4.23B and capital expenditures -903.00M, giving a free cash flow of 3.33B billion.
- Operating Cash Flow
- 4.23B
- Free Cash Flow
- 3.33B
- Free Cash Flow per Share
- 2.30
Dividends & Yields
Boston Scientific pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 5.08%
- Earnings Yield
- 5.33%
Stock Price Statistics
- Beta
- 0.22
- 52-Week Price Change
- ―
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Boston Scientific upcoming earnings date is Feb 03, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 28, 2026
- Next Earnings Date
- Feb 03, 2027
- Ex-Dividend Date
- ―
Financial Position
Boston Scientific as a current ratio of 1.62, with Debt / Equity ratio of 51.24%
- Current Ratio
- 1.62
- Quick Ratio
- 1.08
- Debt to Market Cap
- 0.08
- Net Debt to EBITDA
- 2.03
- Interest Coverage Ratio
- 11.38
Taxes
In the past 12 months, Boston Scientific has paid 493.00M in taxes.
- Income Tax
- 493.00M
- Effective Tax Rate
- 0.15
Enterprise Valuation
Boston Scientific EV to EBITDA ratio is 14.20, with an EV/FCF ratio of 23.08.
- EV to Sales
- 3.65
- EV to EBITDA
- 14.20
- EV to Free Cash Flow
- 23.08
- EV to Operating Cash Flow
- 18.15
Balance Sheet
Boston Scientific has CHF 609.00M in cash and marketable securities with CHF 11.95B in debt, giving a net cash position of -CHF 11.34B billion.
- Cash & Marketable Securities
- CHF 609.00M
- Total Debt
- CHF 11.95B
- Net Cash
- -CHF 11.34B
- Net Cash Per Share
- -CHF 7.83
- Tangible Book Value Per Share
- CHF 0.19
Margins
Gross margin is 70.37%, with operating margin of 21.05%, and net profit margin of 16.56%.
- Gross Margin
- 70.37%
- Operating Margin
- 21.05%
- Pretax Margin
- 17.35%
- Net Profit Margin
- 16.56%
- EBITDA Margin
- 25.70%
- EBIT Margin
- 20.61%
Analyst Forecast
The average price target for Boston Scientific is CHF 40.76, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- CHF 40.76
- Price Target Upside
- ―
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 22
- Revenue Growth Forecast
- 2.10%
- EPS Growth Forecast
- 17.74%
Scores
- Smart Score
- 7
- AI Score
- ―
